Dogwood Therapeutics, Inc. Amortization of Debt Issuance Costs
Dogwood Therapeutics, Inc. (DWTX) reported Amortization of Debt Issuance Costs of $52.37 thousand for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-18.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:AmortizationOfFinancingCosts · last filed 2026-08-14
- Dogwood Therapeutics, Inc. amortization of debt issuance costs for the quarter ending 2025-06-30 was $0.00.
- Dogwood Therapeutics, Inc. amortization of debt issuance costs for the quarter ending 2025-03-31 was $52.37K.
- Dogwood Therapeutics, Inc. amortization of debt issuance costs for the quarter ending 2020-12-31 was $11.91K.
- Dogwood Therapeutics, Inc. amortization of debt issuance costs for the quarter ending 2020-09-30 was $14.75K.
- Dogwood Therapeutics, Inc. amortization of debt issuance costs for fiscal 2025 was $52.37K, a 10.37% decline from fiscal 2024.
- Dogwood Therapeutics, Inc. amortization of debt issuance costs for fiscal 2024 was $58.43K.
- Dogwood Therapeutics, Inc. amortization of debt issuance costs for fiscal 2021 was $0.00, a 100.00% decline from fiscal 2020.
- Dogwood Therapeutics, Inc. amortization of debt issuance costs for fiscal 2020 was $53.98K.
| Period end | Amortization of Debt Issuance Costs 3 month | Amortization of Debt Issuance Costs 6 month | Amortization of Debt Issuance Costs 9 month | Amortization of Debt Issuance Costs 12 month |
|---|---|---|---|---|
| 2025-12-31 | $52.37K 10-K · filed 2026-03-18 | |||
| 2025-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-14 | $52.37K 10-Q · filed 2026-08-14 | ||
| 2025-03-31 | $52.37K 10-Q · filed 2026-05-15 | |||
| 2024-12-31 | $58.43K 10-K · filed 2026-03-18 | |||
| 2021-12-31 | $0.00 10-K · filed 2022-03-18 | |||
| 2020-12-31 | $11.91K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-18 | $26.66K derived: sum of 2 quarters · filed 2022-03-18 | $43.36K derived: sum of 3 quarters · filed 2022-03-18 | $53.98K 10-K · filed 2022-03-18 |
| 2020-09-30 | $14.75K derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-12 | $31.45K derived: sum of 2 quarters · filed 2021-11-12 | $42.07K 10-Q · filed 2021-11-12 | |
| 2020-06-30 | $16.70K derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-13 | $27.32K 10-Q · filed 2021-08-13 | ||
| 2020-03-31 | $10.62K 10-Q · filed 2021-05-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Lite Strategy, Inc. (LITS) | United States | $0.049B | |
| Elicio Therapeutics, Inc. (ELTX) | United States | $0.049B | |
| Werewolf Therapeutics, Inc. (HOWL) | United States | $0.047B | |
| Grace Therapeutics, Inc. (GRCE) | $0.046B | -1.83 | |
| Xilio Therapeutics, Inc. (XLO) | United States | $0.052B | |
| PDS Biotechnology Corp (PDSB) | United States | $0.045B | |
| SCYNEXIS INC (SCYX) | United States | $0.045B | |
| Serina Therapeutics, Inc. (SER) | United States | $0.054B | -2.35 |
| Clene Inc. (CLNN) | United States | $0.054B | -1.99 |
| HERON THERAPEUTICS, INC. /DE/ (HRTX) | United States | $0.055B | -2.38 |